Fulcrum Therapeutics to Present at 31st FSHD Society Research Congress

June 12, 2024 — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a biopharmaceutical company in the clinical-stage focusing on advancing small molecules for the treatment of rare genetic diseases, has disclosed its upcoming presentations at the 31st Annual FSHD Society International Research Congress. This event will take place from June 13-14, 2024, in Denver, Colorado. The company will present an abstract detailing the baseline characteristics of patients participating in the Phase 3 REACH trial for losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD).

The scheduled presentations include:

1. Title: Characteristics of the Enrolled Population in the Phase 3 REACH Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Poster Number: P7.01
- Format: Poster
- First Author: Nicol Voermans, MD, PhD, Radboud University Medical Center
- Presentation Date and Time: Thursday, June 13, 2024, from 5:30 PM to 8:30 PM MDT

2. Title: Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms
- Presentation Number: S6.06
- Format: Oral Presentation
- Presenter: Joost Kools, MD, Radboud University Medical Center
- Presentation Date and Time: Friday, June 14, 2024, at 3:50 PM MDT

3. Title: Safety and Tolerability of Losmapimod for the Treatment of FSHD
- Poster Number: P6.05
- Format: Poster
- First Author: Mihaela Levitchi Benea, MD, Executive Director of Medical Affairs at Fulcrum Therapeutics
- Presentation Date and Time: Thursday, June 13, 2024, from 5:30 PM to 8:30 PM MDT

4. Title: Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in Facioscapulohumeral Muscular Dystrophy
- Poster Number: P7.06
- Format: Poster
- First Author: Lena Hubig, Acaster Lloyd Consulting
- Presentation Date and Time: Thursday, June 13, 2024, from 5:30 PM to 8:30 PM MDT

About Fulcrum Therapeutics

Fulcrum Therapeutics is dedicated to developing small molecule therapies to enhance the quality of life for patients with rare genetic conditions. The company’s primary focus is on areas with significant unmet medical needs. Their leading clinical programs include losmapimod, aimed at treating FSHD, and pociredir, which is designed to boost fetal hemoglobin expression and is under development for sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum leverages unique technology to identify drug targets that can adjust gene expression to address the underlying cause of gene mis-expression.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!